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The advent of endovascular repair of the thoracic aorta (thoracic endovascular aortic repair [TEVAR]) has altered 
the management algorithm for pathologies that affect the 
aortic arch and descending thoracic aorta. In recent years, the 
number of thoracic endovascular procedures has risen.1,2 The 
increased use of TEVAR has been driven by the early mortality 
advantage reported when endovascular therapy is compared 
with open surgical treatment of the thoracic aorta.3,4 TEVAR 
is now considered the first-line therapy for isolated aneurysms 
of the descending thoracic aorta and acute complicated type B 
aortic dissections.2,5–8 In the abdominal aorta, the early mortality 
advantage associated with endovascular repair of abdominal 
aneurysms was lost as a result of late aortic rupture.9 It has been 
suggested that long-term durability may be related to individual 
preoperative aneurysm morphology.10 There is a concern that a 
similar “catch-up” phenomenon might affect procedures in the 
thoracic aorta. At present, midterm to long-term data regarding 
the fate of patients treated with thoracic endografts are sparse, 
and it remains difficult to define whether TEVAR offers a durable 
solution to prevent aortic-related death. The fate of the aorta after 
endovascular treatment for chronic type B aortic dissection is of 
particular concern, and some experts suggest that TEVAR is not 
a viable alternative to open surgical repair in this pathology.11
Editorial see p 5  
Clinical Perspective on p 32
Given the spectrum of different pathologies that affect the 
descending thoracic aorta, it is important to define whether the 
outcome of TEVAR is pathology specific to refine procedural 
technique and endograft design. Careful analysis of long-term 
Background—Endovascular repair of the thoracic aorta has become an increasingly utilized therapy. Although the short-
term mortality advantage over open surgery is well documented, late mortality and the impact of presenting pathology on 
long-term outcomes remain poorly reported.
Methods and Results—A database was built from 5 prospective studies and a single institutional series. Rates of perioperative 
adverse events were calculated, as were midterm death and reintervention rates. Multivariate analysis was performed with 
the use of logistic regression modeling. Kaplan-Meier survival curves were drawn for midterm outcomes. The database 
contained 1010 patients: 670 patients with thoracic aortic aneurysm, 195 with chronic type B aortic dissection, and 114 
with acute type B aortic dissection. Lower elective mortality was observed in patients with chronic dissections (3%) 
compared with patients with aneurysms (5%). Multivariate analysis identified age, mode of admission, American Society of 
Anesthesiologists grade, and pathology as independent predictors of 30-day death (P < 0.05). In the midterm, the all-cause 
mortality rate was 8, 4.9, and 3.2 deaths per 100 patient-years for thoracic aortic aneurysm, acute type B aortic dissection, 
and chronic type B aortic dissection, respectively. The rates of aortic-related death were 0.6, 1.2, and 0.4 deaths per 100 
patient-years for thoracic aortic aneurysm, acute type B aortic dissection, and chronic type B aortic dissection, respectively.
Conclusions—This study indicated that the midterm outcomes of endovascular repair of the thoracic aorta are defined by 
presenting pathology, associated comorbidities, and mode of admission. Nonaortic mortality is high in the midterm for 
patients with thoracic aortic aneurysm, and managing modifiable risk factors appears vital. Endovascular repair of the 
thoracic aorta results in excellent midterm protection from aortic-related mortality, regardless of presenting pathology. 
(Circulation. 2013;127:24-32.)
Key Words: acute aortic syndrome ■ aneurysm ■ aortic dissection ■ endovascular surgery ■ pathology
© 2013 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.112.110056
Continuing medical education (CME) credit is available for this article. Go to http://cme.ahajournals.org to take the quiz.
Received April 4, 2012; accepted October 26, 2012.
From St. George’s Vascular Institute, London, UK (B.P., P.H., M.T.); University of Rostock, Rostock, Germany (C.N.); Massachusetts General Hospital, 
Boston, MA (R.C.); and Hospital of the University of Pennsylvania, Philadelphia (R.F.).
The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA. 
112.110056/-/DC1.
Correspondence to Matt Thompson, MD, FRCS, St. George’s Vascular Institute, 4th Floor, St. James Wing, St. George’s Hospital National Health 
Service Trust, London SW17 0QT, United Kingdom. E-mail matt.thompson@stgeorges.nhs.uk
Aortic Pathology Determines Midterm Outcome After 
Endovascular Repair of the Thoracic Aorta
Report From the Medtronic Thoracic Endovascular Registry  
(MOTHER) Database
Benjamin Patterson, BSc, MRCS; Peter Holt, PhD, FRCS; Chrisoph Nienaber, MD; Richard Cambria, 
MD; Ronald Fairman, MD; Matt Thompson, MD, FRCS
19335
Cardiovascular Surgery
 by guest on January 13, 2014http://circ.ahajournals.org/Downloaded from 
Patterson et al  Pathology Determines Outcomes of TEVAR  25
results will be required to define which subsets of patients 
benefit most from endovascular therapy and to modify man-
agement algorithms according to the pathology treated.
Methods
Trials
Data from 5 prospective trials were obtained from Medtronic, Santa 
Rosa, CA, and collated with the addition of institutional data from 
a single UK center. The collated data were termed the Medtronic 
Thoracic Endovascular Registry (MOTHER). The registry consisted 
of the endovascular arm of 1 phase II/III trial (VALOR I5), the inter-
vention arm of 1 randomized controlled trial (Investigation of Stent 
Grafts in Aortic Dissection [INSTEAD]12), and 3 phase IV trials 
(VALOR II, Captivia, and Valiant Thoracic Stent Graft Evaluation 
For the Treatment of Descending Thoracic Aortic Dissections Trial 
[VIRTUE]13). The institutional data included all TEVARs performed 
over a period of 8 years that used either the Talent or Valiant stent 
graft systems that were not entered into any of the registries (Table 1). 
All of the trials had stringent protocols for collection and validation. 
The institutional series was prospectively maintained, and follow-up 
was by computed tomography.
Patient Data
More than half of the data were from prospective, fully monitored tri-
als with committee consensus adjudication of major adverse events. 
Two clinicians examined all of the adverse events in the St George’s 
Vascular Institute (SGVI) series independently, and any disagree-
ments were discussed before a final decision was made. There was 
emphasis on the occurrence of death, stroke (which included tran-
sient ischemic attack), acute spinal cord injury, and endograft-related 
events requiring reintervention. Deaths were classified as aortic or 
nonaortic. Aortic-related death was defined as any death that was di-
rectly attributable to the index procedure, any subsequent reinterven-
tion, aortic rupture, or aortic complication. The patient cohort was 
stratified into 3 groups determined by presenting pathology: thoracic 
aortic aneurysm (TAA), acute type B aortic dissection ( < 2 weeks 
after symptom onset), and chronic type B aortic dissection (>2 weeks 
after symptom onset). There were insufficient patients with other 
pathologies (eg, transection, mycotic aneurysm) for individual sub-
group analysis.
Statistical Analysis
Data from each source were pooled and analyzed with the use of SPSS 
20 software (IBM, Armonk, NY). The preoperative characteristics 
of each group were examined with the ANOVA test for variance for 
continuous variables and the [chi]2 test for categorical variables. The 
difference in the incidence of postoperative 30-day outcomes between 
each pathological group was tested with the [chi]2 test. A univariate 
analysis for the strength of the association of preoperative characteristics 
with outcomes occurring before 30 days was performed with the Fisher 
exact test. Those variables with a P value of  < 0.1 were entered into 
a binary logistic regression model that incorporated backward variable 
selection to model 30-day death. The Wald test for significance was 
performed at each step to determine the contribution of each variable 
to the model based on the odds ratio (OR) and 95% confidence interval 
(CI). A significance level of 0.05 was set for entry, and 0.1 was used 
for removal of covariates. A maximum number of 20 iterations were 
set as criteria for termination of the process. For the deaths occurring 
at midterm follow-up, candidate variables were screened by plotting 
separate Kaplan-Meier curves for patients with and without that 
specific characteristic. Those variables that achieved a log-rank test of 
P < 0.1 were entered into a Cox regression model. A backward selection 
technique was used to determine which factors would be included in the 
final model with the use of the Wald test for significant contribution to 
the model at each step. Hazard ratios were calculated with 95% CIs with 
a P value for significance from the Wald test. Kaplan-Meier curves were 
constructed for survival in each pathological group, and separate curves 
were plotted for all-cause death, aortic death, nonaortic death, and 
freedom from reintervention. The log-rank test was used to determine 
whether there was a difference between each pathological group.
Results
Demographics
The MOTHER database contained 1010 patients: 670 patients 
with TAA, 114 patients with acute type B aortic dissection, 
Table 1. Sources of Information That Comprised the MOTHER Database
Registry No. NCT Identifier Stent Indication Purpose/End Point Duration
VALOR5 359 00604799 Talent Test: TAA with low/moderate risk (comparator 
with OSR); registry: as for test but not for 
comparison; high-risk: not suitable for OSR 
or high risk (TAA = 333; chronic type B 
aortic dissection = 13; acute type B aortic 
dissection = 8)
Phase II/III study to determine 
success of aneurysm 
treatment
5-y follow-up  
(2003–2011)
VALOR II 160 00413231 Valiant TAA only in patients who are candidates for 
OSR with low/moderate risk
Trial conducted under 
investigational device 
exemption to assess clinical 
performance
5-y follow-up  
(2006–2014)
Captivia 68 01181947 Valiant, Captivia All indications (included TAA = 49; chronic type 
B aortic dissection = 23; acute type B aortic 
dissection = 19; other = 8)
Phase IV trial to evaluate 
midterm clinical performance
3-y follow-up  
(2010–2013)
VIRTUE13 100 01213589 Valiant, Xcelerant Acute type B aortic dissection = 50; chronic type 
B aortic dissection = 50
Collection of safety, 
performance, and health 
economic data
3-y follow-up  
(2006–2012)
INSTEAD12 100 00525356 Talent Chronic type B aortic dissection Phase III comparison of stent 
vs medical therapy in chronic 
dissection
5-y follow-up  
(2002–2011)
SGVI 223 … Talent/Valiant All indications (included TAA = 128; acute type 
B aortic dissection = 37; chronic type B aortic 
dissection = 41; other = 17)
Institutional series of TEVAR 
with Medtronic stent grafts
Variable follow-up 
(2002–2010)
INSTEAD indicates Investigation of Stent Grafts in Aortic Dissection; MOTHER, Medtronic Thoracic Endovascular Registry; NCT, National Clinical Trial; OSR, open 
surgical repair; SGVI, St George’s Vascular Institute; TAA, thoracic aortic aneurysm; TEVAR, thoracic endovascular aortic repair; and VIRTUE, Valiant Thoracic Stent Graft 
Evaluation For the Treatment of Descending Thoracic Aortic Dissections Trial. 
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and 195 patients with chronic type B aortic dissection. The 
demographics of the 3 pathological groups are tabulated in 
Table 2. There were significant differences in demographics 
between the 3 groups of patients, and patients with TAA were 
older and had significantly higher rates of comorbidity than 
patients with either acute or chronic dissection. Patients with 
acute type B aortic dissection were universally treated non-
electively. Of additional interest was the low incidence of dia-
betes mellitus in patients with acute but not chronic dissection.
The Ishimaru zone classification refers to the final posi-
tion of the leading edge of the stent graft after deployment. 
Overall, 394 patients had the left subclavian artery covered 
by the endografts, and 143 of these patients had a subclavian 
revascularization by either carotid-subclavian bypass or trans-
position. The policy toward revascularization was defined 
by each institution involved in the individual studies. In the 
SGVI series, revascularization was performed in the majority 
of elective cases in which this was technically feasible.
Mean follow-up time for the TAA patients was 3.1 years 
(median, 2.7; interquartile range, 0.9–5.6), for chronic type B 
aortic dissection patients 2.4 years (median, 2.0; interquartile 
range, 1.5–3.2), and for acute type B aortic dissection patients 
2.2 years (median, 2.0; interquartile range, 0.4–3.4).
Early Outcomes (30-Day and In-Hospital Results)
Death, stroke, and acute spinal cord ischemia were reported 
for elective and nonelective TEVAR with respect to pathol-
ogy (Tables 3 and 4). In patients undergoing elective sur-
gery, which consisted of patients with TAA and chronic type 
B aortic dissection only, there were more deaths (5% versus 
Table 2. Demographics Between Patients Who Were Treated for Thoracic Aortic Aneurysm, Acute Type B Aortic Dissection, and 
Chronic Type B Aortic Dissection
Thoracic Aortic Aneurysm Chronic Type B Aortic Dissection Acute Type B Aortic Dissection P
n 670 195 114
Male sex, n (%) 399 (59) 161 (83) 87 (76) <0.001
Age, y (range) 71.4 (25–89) 63.1 (28–94) 61.4 (25–83) <0.001
GAS (range) 79.1 (27–112) 68.3 (28–103) 66.3 (25–107) <0.001
AAA, n (%) 167 (25) 22 (11) 17 (14) <0.001
Renal impairment, n (%) 129 (20) 21 (12) 12 (11) <0.001
Hypertension, n (%) 552 (83) 182 (83) 73 (93) <0.001
Diabetes mellitus, n (%) 109 (17) 22 (11) 3 (3) <0.001
COPD, n (%) 227 (34) 20 (11) 10 (9) <0.001
Cerebrovascular disease, n (%) 115 (17) 6 (3) 5 (4.2) <0.001
Smoking history, n (%) 452 (70) 109 (61) 56 (53) <0.001
Cardiac disease, n (%) 269 (43) 33 (20) 18 (18) <0.001
Peripheral vascular disease, n (%) 125 (22) 6 (6.7) 3 (4) <0.001
Hyperlipidemia, n (%) 311 (52) 42 (48) 34 (43) 0.962
ACEi, n (%) 178 (26) 58 (31) 15 (13) <0.001
[beta]-Blocker, n (%) 267 (62) 73 (65) 22 (55) 0.519
Calcium channel blocker, n (%) 146 (34) 23 (55) 13 (33) 0.018
Statins, n (%) 230 (53) 28 (62) 14 (35) <0.001
Nonelective, n (%) 38 (6) 16 (8) 114 (100) <0.001
ASA, n (%)
 1 17 (3) 26 (15) 4 (4) <0.001
 2 111 (18) 54 (28) 23 (22)
 3 345 (52) 72 (37) 31 (26)
 4 139 (21) 26 (14) 41 (35)
 5 11 (2) 1 (1) 8 (7)
 Missing 45 (7) 14 (7) 11 (9)
Ishimaru, n (%)
 0 5 (1) 2 (1) 3 (3)
 1 44 (7) 16 (8) 4 (4)
 2 192 (29) 67 (35) 61 (54)
 3 260 (39) 101 (52) 38 (32)
 4 163 (24) 7 (4) 8 (7)
AAA indicates abdominal aortic aneurysm; ACEi, angiotensin-converting enzyme inhibitor; ASA, American Society of Anesthesiologists score; GAS, Glasgow Aneurysm 
Score; and Ishimaru, Ishimaru landing zone classification. Statistical analysis used ANOVA and χ2 test for difference in continuous and categorical variables, respectively. 
Percentages take into account missing data.
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by each institution involved in the individual studies. In the 
SGVI series, revascularization was performed in the majority 
of elective cases in which this was technically feasible.
Mean follow-up time for the TAA patients was 3.1 years 
(median, 2.7; interquartile range, 0.9–5.6), for chronic type B 
aortic dissection patients 2.4 years (median, 2.0; interquartile 
range, 1.5–3.2), and for acute type B aortic dissection patients 
2.2 years (median, 2.0; interquartile range, 0.4–3.4).
Early Outcomes (30-Day and In-Hospital Results)
Death, stroke, and acute spinal cord ischemia were reported 
for elective and nonelective TEVAR with respect to pathol-
ogy (Tables 3 and 4). In patients undergoing elective sur-
gery, which consisted of patients with TAA and chronic type 
B aortic dissection only, there were more deaths (5% versus 
3%, respectively), strokes (5% versus 2%), and acute spinal 
cord injuries (5% versus 3%) after TEVAR for TAA. Twice 
as many patients were affected by a major adverse event in 
the TAA group (14% versus 7%). Nonelective surgery caused 
more deaths, with most occurring in the TAA group (18% ver-
sus 13% versus 11% in TAA, chronic type B aortic dissection, 
and acute type B aortic dissection, respectively). The rate of 
stroke was equivalent (5% versus 7% versus 6%, respectively), 
but there was a higher incidence of spinal cord injury in the 
TAA group (11% versus 0% versus 2%, respectively). Of the 
42 incidences of spinal cord injury, 15 resulted in paraplegia 
and 27 in paraparesis. In the 20 patients in whom data were 
available, 12 had resolution of symptoms. The causes of death 
for each group of patients are illustrated in Table 5, tabulated 
according to whether the death occurred early (at 30 days) or 
later in follow-up.
Modeling 30-Day Outcomes
Regression modeling identified that the factors that predicted 
mortality at 30 days were as follows: age (OR, 1.048 [per 
additional year]); 95% CI, 1.016–1.080; P = 0.003), Ameri-
can Society of Anesthesiologists (ASA) grade (OR, 2.339 
[per additional point]; 95% CI, 1.563–3.500; P < 0.001), and 
emergency admission (OR, 2.497; 95% CI, 1.270–4.908; 
P = 0.008). If mode of admission was excluded from the 
analysis (because this was highly influenced by pathology), 
then a different model was generated with different signifi-
cant predictor variables including age (OR, 1.051, 95% CI, 
1.018–1.085; P = 0.002), ASA grade (OR, 2.362, 95% CI, 
1.615–3.455; P < 0.001), and aortic pathology (TAA [OR, 1, 
assumed in comparison with dissection]; acute type B aortic 
dissection [OR, 2.32; 95% CI, 1.043–5.176; P = 0.0239]; and 
chronic type B aortic dissection [OR, 1.124; 95% CI, 0.442–
2.859; P = 0.81]). The model that included mode of admission 
appeared to have slightly greater discriminatory power with a 
C statistic of 0.760 versus 0.733 in the pathology-based model 
(both P =  < 0.005).
Midterm Clinical Outcome
Life table analysis for all-cause mortality (Figure, panel A) 
showed that the early death rate was highest in the acute type 
B aortic dissection group and that after this initial period, the 
mortality curve assumed a similar trajectory and ran parallel 
to that of the chronic type B aortic dissection group. The TAA 
curve revealed an early death rate that lay between those of 
acute and chronic dissection but over the midterm continued 
to trend downward in a steeper trajectory than either acute or 
chronic dissection. Analysis of mortality from non–aortic-
related (Figure, panel B) and aortic-related mortality (Figure, 
panel C) suggested that the excess mortality in the TAA group 
compared with the patients with dissection was principally 
accounted for by nonaortic death. Freedom from all-cause 
mortality by life table analysis over the whole period of fol-
low-up was 56% in the TAA group, 64% in the chronic type B 
aortic dissection group, and 42% in the acute type B aortic dis-
section group. Freedom from aortic death was 93%, 96%, and 
85%, respectively. All of the Kaplan-Meier plots for mortality 
demonstrated significant difference between the 3 pathology 
groups (P < 0.002). The causes of deaths during the follow-up 
period are illustrated in Table 5; few of the late deaths in all 
groups were related to the primary, treated, aortic pathology.
The death rate per 100 patient-years at maximum follow-up 
was calculated for all patients in the 3 main pathology groups 
who had not died or been censored at [mtequ]90 days. The 
mortality rate was 8, 4.9, and 3.2 per 100 patient-years, and 
the aortic-related mortality rate was 0.6, 1.2, and 0.4 per 100 
patient-years for TAA, acute type B aortic dissection, and 
chronic type B aortic dissection, respectively.
Statistical analysis with the use of Cox proportional hazards 
modeling revealed that the differences in overall mortality 
between the 3 groups of patients were influenced by variables 
that included age (hazard ratio, 1.037 per additional year; 
95% CI, 1.021–1.054; P < 0.001); the presence of previous 
cerebrovascular disease (hazard ratio, 1.48; 95% CI, 1.03–
2.12; P = 0.034); a history of renal failure (hazard ratio, 1.62; 
95% CI, 1.17–2.24; P = 0.004); and ASA grade (hazard ratio, 
1.36 per additional grade; 95% CI, 1.11–1.68; P = 0.004).
Reintervention and Aortic-Related Complications
The rate of aortic-related death in both dissection groups 
appears to plateau markedly before the 12-month time point; 
after that period, there appear to be relatively few aortic-related 
deaths. This is clearly of significance in defining whether 
endovascular therapy can prevent aortic-related deaths in type 
B aortic dissection.
Life table analysis of freedom from reintervention 
(Figure, panel D) showed that the highest rate of 
intervention in the postoperative period was in the acute 
Table 3. Thirty-Day Outcomes For Patients Undergoing 
Elective Thoracic Endovascular Aortic Repair
Thoracic Aortic 
Aneurysm  
(n = 625)
Chronic Type B Aortic 
Dissection (n = 179)
Death, n (%) 33 (5) 6 (3)
Stroke, n (%) 34 (5) 3 (2)
Spinal cord injury, n (%) 30 (5) 6 (3)
All acute type B dissections were treated nonelectively. Numbers in this table 
varied from those in Table 1 because 7 subjects were missing admission data 
for thoracic aortic aneurysm and 1 was missing data for chronic type B aortic 
dissection.
Table 4. Thirty-Day Outcomes For Patients Undergoing Nonelective Thoracic Endovascular Aortic Repair
Thoracic Aortic Aneurysm (n = 38) Chronic Type B Aortic Dissection (n = 15) Acute Type B Aortic Dissection (n = 114)
Death, n (%) 7 (18) 2 (13) 13 (11)
Stroke, n (%) 2 (5) 1 (7) 7 (6)
Spinal cord injury, n (%) 4 (11) 0 (0) 2 (2)
Numbers in this table varied from those in Table 1 because 7 were missing admission data for thoracic aortic aneurysm and 1 was missing data for chronic type B 
aortic dissection.
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type B aortic dissection group followed by the chronic type 
B aortic dissection and TAA groups. Freedom from aortic 
reintervention at 6 years was 84% in the TAA group, 71% 
in the chronic type B aortic dissection group, and 46% in 
the acute type B aortic dissection group. The most common 
cause for reintervention in the TAA group was endoleak, 
most commonly type I (Table 6). This was reflected in the 
most common mode of reintervention, which was proximal 
or distal extension of the main endograft (Table 7). The most 
common reason for reintervention in both dissection groups 
was malperfusion (either ongoing or related to branch 
coverage by an endograft), followed by type II/III endoleak 
in the chronic type B aortic dissection group and further 
aneurysmal expansion in the acute type B aortic dissection 
group. The rate of late reintervention after 90 days was 2.1, 
5.3, and 6.7 per 100 patient-years in TAA, chronic type B 
aortic dissection, and acute type B aortic dissection groups, 
respectively. There was no association between the need for 
aortic reintervention and midterm death.
Discussion
The database used in the present study contained >1000 
patients who had undergone TEVAR with well-validated data 
collection and outcome definition.
The study demonstrated that outcomes after TEVAR were 
pathology specific. This finding has implications for future 
reporting standards because outcomes should be reported for 
specific pathologies rather than for generic procedures. Series 
reporting unstratified, unselected series are likely to miss sub-
tle subgroup effects driven by aortic pathology, which will be 
increasingly important in defining the optimum treatment for 
patients with disease of the thoracic aorta.
Analysis of early outcomes demonstrated that patients 
with TAA had a higher rate of elective adverse outcomes 
than patients with chronic type B aortic dissection. The early 
mortality rate for TAA and chronic type B aortic dissection 
reported in the present study was similar to that described 
in several large series14–16 and considerably better than that 
reported in community analyses.17 The difference in adverse 
outcomes between the elective treatment of TAA and chronic 
type B aortic dissection was related to a higher incidence of 
stroke in patients with aneurysms. This difference may be 
related to the higher burden of cardiovascular disease observed 
in patients with TAA who had higher rates of comorbidities 
than patients with dissection.
All of the patients with acute dissection in the present study 
were treated nonelectively. This reflected that the indication 
for endovascular intervention in these cases was the treat-
ment of complicated acute dissection. The mortality rate for 
acute type B aortic dissection was in agreement with previous 
reports18,19 and, interestingly, was not significantly different 
from the mortality rate for the treatment of TAA or chronic 
type B aortic dissection in the nonelective setting. All groups 
studied exhibited higher adverse outcome rates when treated 
in the nonelective setting, which is intuitive and has been 
reported previously.20
The overall rate of neurological complications (stroke and 
spinal cord injury) in patients with nonelective TAA in the 
present study appears similar to that described elsewhere 
and is clearly a source of major morbidity in this group of 
patients,21–24 although not in the patients with acute or chronic 
dissection. There is no proven explanation for the lower inci-
dence of spinal cord injury in patients with type B aortic dis-
section, although the lower incidence of comorbidities and 
continued perfusion of the false lumen after TEVAR may play 
a role. Disruption of collateral blood supply can affect perfu-
sion of the spinal cord, and patients who undergo a greater 
extent of aortic coverage may be more susceptible to spinal 
cord injury. Coverage of the left subclavian artery may have 
a similar effect, but more high-quality evidence is required 
before a consensus can be reached. Only 4 patients devel-
oped a spinal cord injury after 30 days, suggesting that this is 
chiefly a periprocedural problem.
Regression modeling revealed that age, ASA grade, mode 
of admission (elective versus nonelective), and type of aortic 
pathology were implicated in early mortality, which validates 
previous studies.4,25,26
The midterm results revealed considerable differences 
in mortality and reinterventions with reference to aortic 
pathology. Patients with TAA demonstrated poorer midterm 
survival compared with the patients with aortic dissection. 
Analysis suggested that patients with TAA had an increased 
rate of non–aortic-related mortality. The effectiveness of 
TEVAR in preventing aortic-related death in patients with 
TAA has been suggested by previous studies, which have 
revealed that >90% of patients remain free of aortic-related 
death 5 years after TEVAR.7 These findings were confirmed 
Table 5. Causes of Mortality For Patients Undergoing Thoracic Endovascular Aortic Repair for Thoracic Aortic Aneurysm, Acute 
Type B Aortic Dissection, and Chronic Type B Aortic Dissection
Thoracic Aortic Aneurysm, n (%) Chronic Type B Aortic Dissection, n (%) Acute Type B Aortic Dissection, n (%)
Cause of death <30 d (n = 43) >30 d (n = 176)  <30 d (n = 8) >30 d (n = 19)  <30 d (n = 15) >30 d (n = 13)
Aortic related 13 (30) 16 (9) 1 (13) 3 (15) 5 (39) 5 (30)
Cardiac 7 (16) 48 (27) 2 (25) 4 (20) 3 (23) 0
Neurological 4 (9) 16 (9) 1 (13) 1 (5) 0 1 (6)
Noncardiac, nonneurological 8 (19) 63 (36) 0 3 (15) 1 (8) 0
Respiratory 2 (5) 6 (3) 0 1 (5) 1 (8) 1 (6)
Retrograde type A dissection 2 (5) 1 (1) 1 (13) 1 (5) 2 (16) 2 (12)
Other/unknown 7 (16) 26 (15) 3 (38) 6 (30) 1 (8) 6 (35)
The causes of mortality are given for early (<30 d) and midterm (>30 d) mortality. In this table, 3 patients had missing mode of admission data.
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by the present study. The majority of deaths after TEVAR 
for TAA were due to cardiac, respiratory, and miscellaneous 
causes (including cancer, which is not well defined in the 
data set), which has been reported previously in a series 
of patients undergoing treatment for both thoracic and 
abdominal aneurysms.2,21,27 Patients with TAA have significant 
comorbidity, which is reflected in a high non–aortic-related 
mortality rate after therapy for aneurysmal disease. It is 
perhaps relevant that only 53% of patients with TAA in the 
present study were taking statins. Interestingly, when the rate 
of death (8 deaths per 100 patient-years) was calculated for 
patients with TAA, it was remarkably similar to the rate of 
Figure. A, Kaplan-Meier estimates for total survival in the 3 groups of patients up to 6 years of follow-up. The numbers of patients at risk 
are given below the graph. Log-rank test P = 0.002. A-BD indicates acute type B aortic dissection; C-BD, chronic type B aortic dissec tion; 
and TAA, thoracic aortic aneurysm. B, Kaplan-Meier estimates for freedom from non–aortic-related death in the 3 groups of patients up 
to 6 years of follow-up. The numbers of patients at risk are given below the graph. Log-rank test P < 0.001. C, Kaplan-Meier estimates 
for freedom from aortic-related death in the 3 groups of patients up to 6 years of follow-up. The numbers of patients at risk are given 
below the graph. Log-rank test P < 0.001. D, Kaplan-Meier estimates for freedom from aortic-related reintervention in the 3 groups of 
patients up to 6 years of follow-up. The numbers of patients at risk are given below the graph. Log-rank test P =  < 0.001. Re-int. indicates 
reintervention.
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death reported for patients with abdominal aortic aneurysm in 
the Endovascular Aneurysm Repair (EVAR)-1 study.9 Clearly, 
attention needs to be directed toward the medical management 
of cardiovascular risk factors in patients with aneurysms 
undergoing endovascular repair.
The 2 groups of patients with aortic dissection had differ-
ing patterns of midterm outcomes when subjectively com-
pared with the patients with TAA. Importantly, after the initial 
differences in perioperative death, the curves for survival in 
acute and chronic dissection run parallel. This is a reflection 
of data quality because acute dissection becomes chronic 
after 2 weeks, and the natural history in the 2 groups might be 
expected to be similar after the effects of initial presentation 
and treatment have become manifest.
One of the crucial issues affecting endovascular therapy in 
patients with type B aortic dissection is whether TEVAR con-
fers protection from aortic-related death in the mid to long 
term. It appears well established that TEVAR for both acute 
and chronic type B aortic dissection offers significant advan-
tages over open surgery with respect to 30-day mortality and 
major morbidity.19,28 However, open surgery offers a robust 
solution to preventing aortic-related death over long-term fol-
low-up,29 whereas the outcome after endovascular therapy is 
not as well defined, with uncertainty over the morphology of 
the distal aorta after TEVAR.30 The present study has revealed 
that patients with both acute and chronic aortic dissection 
have low rates of aortic-related mortality in the midterm after 
TEVAR. After the initial perioperative phase, aortic-related 
mortality is low, which suggests that endovascular therapy has 
the potential to confer prevention of aortic dissection and rup-
ture over a reasonable time period. This effect appears to be 
dependent on aortic surveillance and subsequent intervention 
because rates of aortic reintervention in patients with acute 
and chronic type B aortic dissection were higher than those 
described for patients with TAA. However, patients can go 
on to develop complications at 5 to 10 years after endovascu-
lar surgery for aortic problems, and more long-term data are 
crucial in further characterizing the incidence of late aortic 
complications and mortality. A useful addition to the present 
study would have been more detailed morphological analy-
sis of postoperative imaging to describe subsequent aortic 
remodeling because this remains relatively poorly studied. 
Unfortunately, access to individual preoperative and postop-
erative imaging was limited to the single-center series.
The occurrence of retrograde type A dissection should not 
be underestimated after TEVAR, and the present study has 
again demonstrated that this complication occurs with a higher 
incidence in patients with aortic dissection than in those with 
Table 7. Mode of Reintervention for Patients Undergoing Thoracic Endovascular Aortic Repair for Thoracic Aortic Aneurysm, Acute 
Type B Aortic Dissection, and Chronic Type B Aortic Dissection
Mode of Reintervention Thoracic Aortic Aneurysm Chronic Type B Aortic Dissection Acute Type B Aortic Dissection
Total No. 70 34 29
Open thoracic aortic surgery 1 (1) 2 (6) 2 (7)
Open abdominal aortic surgery 2 (2) 0 2 (7)
Endovascular repair of abdominal aorta 0 3 (9) 1 (3)
Supra-aortic bypass 0 1 (3) 4 (14)
Stent of other artery 0 5 (15) 2 (7)
Proximal/distal extension of stent graft/additional stent graft 48 (69) 12 (35) 8 (28)
Left subclavian artery embolization/plug 12 (17) 5 (15) 2 (7)
Hybrid open/endovascular procedure 3 (4) 2 (6) 0
Other 4 (6) 4 (12) 8 (28)
Numbers in parentheses represent the percentage of total reinterventions each category contributes.
Table 6. Causes of Reintervention for Patients Undergoing Thoracic Endovascular Aortic Repair for Thoracic Aortic Aneurysm, 
Acute Type B Aortic Dissection, and Chronic Type B Aortic Dissection
Indication for Intervention Thoracic Aortic Aneurysm Chronic Type B Aortic Dissection Acute Type B Aortic Dissection
Total No. 70 34 29
Aneurysmal expansion of aorta 5 (7) 4 (12) 6 (21)
Continued perfusion of false lumen 0 5 (15) 0
Extension of dissection 0 4 (12) 4 (14)
Malperfusion 0 7 (21) 9 (31)
Rupture of aorta 0 1 (3) 1 (3)
Stent migration 4 (6) 0 0
Type I endoleak 25 (36) 4 (12) 1 (3)
Type II/III endoleak 20 (29) 8 (24) 2 (7)
Other endoleak 15 (21) 0 0
Unknown 1 (1) 1 (3) 6 (21)
Numbers in parentheses represent the percentage of total reinterventions each category contributes.
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aneurysmal disease. Data from the International Registry of 
Aortic Dissection suggest that the rate of retrograde type A 
dissection is 1.3% to 2.4%,31 but a recent systematic review 
found the rate to be 3.2% after TEVAR for acute type B aor-
tic dissection, 1.5% for chronic type B aortic dissection, and 
0.5% for TAA. At midterm follow-up, this rate increased to 
4.9% in acute type B aortic dissection patients and 2.3% in 
chronic type B aortic dissection patients, indicating that some 
patients are at risk of this devastating complication after the 
initial perioperative period (B. Patterson, MD, et al, unpub-
lished data, 2011).
The factors that influenced midterm survival in the present 
study were advancing age, the presence of preoperative cere-
brovascular and renal disease, and ASA grade. These factors 
appear to be a reflection of the burden of systemic disease and 
are not dissimilar to those reported by Lee et al15 in a series of 
400 patients.
An important limitation of our study is that the 5 trials that 
were used for pooled analysis all collected slightly different 
data, both preoperatively and postoperatively. This meant that 
some important elements could not be studied, such as the 
influence of medical risk factor control on midterm survival. 
Although most trials had independent adjudication of end 
points, it was not always possible to accurately record cause 
of death, which may have led to underestimation of the deaths 
in each category during the survival analyses. Importantly, 
some aneurysm-related deaths may have been recorded as 
“unknown,” but on the basis of most reported series, it is 
unlikely that there were many. Surgeon experience and peri-
operative care have advanced over the last decade, and the care 
of patients operated on early in the registries may not reflect 
current practice. This is unavoidable when one studies mid-
term and long-term follow-up for most elements of medical 
practice. Many studies of this kind are criticized for studying 
obsolete first-generation stent graft technology at follow-up. 
In the present study, only 2 devices were used, and both of 
these are still commercially available. Another drawback was 
that access to original imaging was not possible. Analysis of 
such features may provide insight into the effect of morphol-
ogy on outcomes (for example, the effect of transverse arch 
atherosclerotic load on the risk of subsequent neurological 
complications). In addition, many of these patients were oper-
ated on in high-volume centers, many of which were among 
the early adopters of TEVAR. This could reduce the generaliz-
ability of some of these results.
Although the data were derived from 6 individual stud-
ies, all but 1 were multicenter, multinational trials. Specific 
institution, surgeon, and year of the procedure probably had 
more influence than the study into which the patient was 
entered. Unfortunately, all of these factors cannot be con-
trolled for, and this is an inherent weakness of data obtained 
in this fashion rather than the present study specifically. 
No specific methodology that applied to the selection of 
patients or the technical aspects of surgery was any different 
from that used in standard practice. Patients were treated 
as they would usually be at a specific institution. Subgroup 
analysis comparing demographics and adverse outcomes for 
patients with a specific pathology between registries showed 
that there appeared to be few differences between studies, 
but this subdivision analysis resulted in relatively small 
numbers of events (Tables I and II in the online-only Data 
Supplement).
The present study has indicated that the midterm outcomes 
of TEVAR are defined by the aortic pathology treated, the 
associated comorbidities, and the nature of presentation 
(elective or emergent). Reporting of outcomes should stratify 
results according to these factors. In patients with TAA, 
the non–aortic-related mortality is high in the midterm, 
and attention must be focused on managing modifiable risk 
factors. TEVAR appears to offer excellent midterm protection 
from aortic-related mortality for both TAA and type B aortic 
dissection. This protection, however, appears dependent on a 
high rate of aortic reintervention, which should be the focus of 
practice and device development in the future.
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CLINICAL PERSPECTIVE
Endovascular repair is increasingly being adopted as the treatment of choice for many thoracic aortic conditions. As the appli-
cation of this technology widens, developing an evidence-based understanding of which patients are most likely to benefit is a 
priority. A barrier to this has been the relatively few number of procedures that are performed, so that randomized controlled 
trials on the scale of those performed for infrarenal aortic aneurysm have not been feasible. At present, many published series 
fail to discriminate between different aortic pathologies when outcomes are reported, making pooled analysis difficult. This 
first report from the Medtronic Thoracic Endovascular Registry (MOTHER) combines raw data from 5 trials and 1 institutional 
series, characterizing the difference in early outcomes between the major pathology groups. Regional trends in practice suggest 
that thoracic endovascular repair has complemented open surgery rather than replaced it and has allowed more patients to be 
offered therapy than was previously possible. Significantly, some will have been deemed unfit for open surgery because of poor 
physiological reserve, and although thoracic endovascular aortic repair all but abolishes aortic death, individuals remain subject 
to an increased risk of mortality from all other causes in comparison with matched controls. Follow-up data collected for the 
component registries have allowed a description of midterm survival in such patients, and this report serves to highlight the 
importance of considering all-cause mortality in aneurysm patients and to reinforce the ability of thoracic endovascular aortic 
repair to prevent aortic-related death in both aneurysm and dissection patients.
Go to http://cme.ahajournals.org to take the CME quiz for this article.
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p
n
Death	   1 2.3% 11 12.4% 14 4.2% 7 4.4% <0.05
Stroke 3 7.0% 8 9.0% 19 5.7% 4 2.5% 0.12
SCI 0 0.0% 4 4.5% 19 5.7% 5 3.1% 0.276
n
Death	   0 0.0% 3 9.1% 0 0.0% 3 4.5% 0 0.0% 0.273
Stroke 0 0.0% 1 3.0% 0 0.0% 1 1.5% 1 2.1% 0.964
SCI 0 0.0% 1 3.0% 1 0.0% 3 4.5% 1 2.1% 0.336
p
n
Death	   1 16.7% 6 18.8% 0.904
Stroke 0 0.0% 2 6.3% 0.529
SCI 1 16.7% 3 9.4% 0.593
p
n
Death	   1 25.0% 1 12.5% 0 0.0% 0.626
Stroke 0 0.0% 0 0.0% 1 33.3% 0.117
SCI 0 0.0% 0 0.0% 0 0.0% -­‐
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SUPPLEMENTAL	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  I
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Age	  (STD) 62 9.6 60 10.1 64 13.0 59 10.9 0.058
GAS	  (STD) 70 11.1 62 12.0 75 20.0 62 11.8 <0.05
CVA 0 0.0% 1 1.5% 4	  (37) 10.8% 0 0.0% <0.05
Renal	  failure 4 17.4% 0 0.0% 9 22.5% 5 10.0% <0.05
CAD N/A N/A 14 20.6% 8 20.0% 6	  (49) 12.2% 0.467
Resp 1 4.3% 6 8.8% 3	  (30) 10.0% 7 14.0% 0.723
Diabetes 1 4.3% 6 8.8% 6 15.0% 7	  (49) 14.3% 0.526
Chi-­‐sq
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Age	   58 13.4% 66 12.5 63 14.1 0.272
GAS 67 13.8 72 15.5 66.3 15.0 0.314
Gender	  (M) 14 60.9% 27 67.5% 38 76.0% 0.946
CVA 1 4.3% 0 0.0% 2 4.0% 0.42
Renal	  failure 3 13.0% 5 12.5% 3 6.0% 0.36
Cardiac	  disease N/A N/A 7 17.5% 4 8.0% 0.2
Resp 1 4.3% 1 2.5% 7 14.0% 0.188
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  (115) 15.7% 73 21.6% 26 16.3% 0.274
CAD ** -­‐ 39	  (114) 34.2% 144 42.6% 71 44.4% 0.201
Resp 15(47) 31.9% 15	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